{"id":52133,"date":"2025-12-29T12:13:42","date_gmt":"2025-12-29T04:13:42","guid":{"rendered":"https:\/\/flcube.com\/?p=52133"},"modified":"2025-12-29T12:13:43","modified_gmt":"2025-12-29T04:13:43","slug":"novo-nordisks-sogroya-wins-nmpa-approval-for-pediatric-growth-hormone-deficiency","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52133","title":{"rendered":"Novo Nordisk\u2019s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency"},"content":{"rendered":"\n

Novo Nordisk<\/strong> (NYSE:\u202fNVO<\/a>) announced that its once\u2011weekly long\u2011acting growth hormone (LAGH) injection, Sogroya (somapacitan)<\/strong>, received approval from China\u2019s National Medical Products Administration (NMPA)<\/strong> for the treatment of growth retardation in children aged 2.5\u202fyears and older<\/strong> due to insufficient endogenous growth hormone secretion. The approval is based on the REAL6 Chinese study<\/strong>, which demonstrated comparable height velocity to daily somatropin with a lower treatment burden.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Approval Date<\/strong><\/td>22\u202fDec\u202f2025<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Product<\/strong><\/td>Sogroya (somapacitan)<\/td><\/tr>
Indication<\/strong><\/td>Pediatric growth hormone deficiency (PGHD) in children \u22652.5\u202fyears<\/td><\/tr>
Mechanism<\/strong><\/td>Once\u2011weekly long\u2011acting growth hormone (LAGH) injection<\/td><\/tr>
Efficacy Basis<\/strong><\/td>REAL6 Chinese Phase\u202f3 study (110 treatment\u2011na\u00efve patients)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence \u2013 REAL6 Study<\/h2>\n\n\n\n
Parameter<\/th>Sogroya (0.16\u202fmg\/kg\/week)<\/th>Daily Somatropin (0.034\u202fmg\/kg\/day)<\/th>Outcome<\/th><\/tr><\/thead>
Treatment Duration<\/strong><\/td>52\u202fweeks<\/td>52\u202fweeks<\/td>Head\u2011to\u2011head comparison<\/td><\/tr>
Mean Height Velocity (HV)<\/strong><\/td>11.0\u202fcm\/year<\/strong><\/td>Comparable<\/td>Non\u2011inferior efficacy<\/td><\/tr>
Injection Site Reactions<\/strong><\/td>2.7%<\/strong> incidence<\/td>Not reported<\/td>Low local tolerability issues<\/td><\/tr>
Injection Site Pain<\/strong><\/td>0%<\/strong> reported<\/td>Not reported<\/td>Superior patient experience<\/td><\/tr>
Safety Profile<\/strong><\/td>Consistent with daily formulation<\/td>\u2014<\/td>No new safety signals<\/td><\/tr>
Treatment Burden<\/strong><\/td>Significantly lower<\/td>Daily injections<\/td>Improved compliance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
China PGHD Prevalence<\/strong><\/td>~30,000\u201140,000 children (2025)<\/td><10% receive growth hormone therapy<\/td><\/tr>
China Growth Hormone Market<\/strong><\/td>\u00a58\u201110\u202fbillion<\/strong> (\u2248\u202fUS$1.1\u20111.4\u202fB)<\/td>Dominated by daily formulations; LAGH penetration <5%<\/td><\/tr>
Sogroya Peak Sales<\/strong><\/td>\u00a51.5\u20112.5\u202fbillion<\/strong> (\u2248\u202fUS$210\u2011350\u202fM) by 2030<\/td>30\u201140% share of eligible PGHD segment<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Daily somatropin (Novo\u2019s Norditropin, domestic biosimilars)<\/td>First weekly LAGH approved for PGHD in China<\/td><\/tr>
Pricing Strategy<\/strong><\/td>Premium LAGH pricing justified by convenience<\/td>Potential for NRDL inclusion in 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n